Etretinate as an effective adjunctive therapy for recalcitrant palmar/plantar hyperkeratosis in patients with erythrodermic cutaneous T cell lymphoma undergoing photopheresis.
BACKGROUND: Patients with erythrodermic cutaneous T cell lymphoma (CTCL) frequently have debilitating hyperkeratosis of the palms and soles that is refractory to therapy. OBJECTIVE: To evaluate the efficacy of etretinate as an adjunctive therapy for recalcitrant palmar and plantar hyperkeratosis in erythrodermic CTCL patients undergoing photopheresis. METHODS: Five patients with erythrodermic CTCL and recalcitrant palmar and plantar hyperkeratosis were given etretinate (0.8 mg/kg per day) while undergoing photopheresis therapy. RESULTS: There was a rapid and marked improvement of the hyperkeratosis in all patients. CONCLUSION: Etretinate is a safe and effective adjunctive treatment for recalcitrant palmar and plantar hyperkeratosis in erythrodermic CTCL patients undergoing photopheresis.